Resverlogix Announces One-Year Extension of Debenture
Rhea-AI Summary
Resverlogix (RVXCF) announced a one-year extension of its US$6.0 million secured debenture with Hepalink, moving the maturity date to May 13, 2027. The interest rate increases from 18% to 20% per annum starting May 14, 2026, with accrued interest paid.
Positive
- US$6.0 million secured debenture maturity extended to May 13, 2027
- Accrued interest on the Hepalink debenture to be paid as part of extension
- Lender Hepalink continues financial support through formal one-year extension
Negative
- Interest rate on the US$6.0 million debenture rises from 18% to 20%
- Higher annual interest expense begins accruing from May 14, 2026
- Secured debenture obligation remains outstanding for an additional year
News Market Reaction – RVXCF
In the May 12 session, RVXCF gained 7.57%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US
"We appreciate Hepalink's continued support and are pleased with the one-year extension of the debenture," stated Donald McCaffrey, President & CEO of Resverlogix.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).
Follow us on:
- X.com: @Resverlogix_RVX
- LinkedIn: linkedin.com/company/resverlogix-corp-/
Forward-Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296992